Systemic Immune-Inflammation Index May Predict Mortality in Neuroblastoma.

Abstract

Neuroblastomas (NB) are among the most frequent childhood solid tumors. The link between inflammation and cancer is well understood. Many research studies have been conducted to determine the prognostic importance of inflammatory markers in cancer patients.C-reactive protein(CRP), neutrophil-to-lymphocyte ratio(NLR), platelet-to-lymphocyte ratio(PLR), and systemic immune-inflammation index(SII) are all potential inflammation indicators.The purpose of this study is to assess the efficacy of NLR and SII as inflammatory indicators in predicting NB patient survival. Patients with NB diagnosed between January 1, 2012 and December 31, 2021 were studied retrospectively, and death was documented.By dividing the number of neutrophils by the number of lymphocytes, the NLR was obtained. The SII was calculated by multiplying the NLR by the platelet count. 46 patients with NB were included in the study with a mean age of 57.58 months(4.14-170.05).When the patients were analyzed based on mortality the NLR and SII values were statistically significantly increased in the dead group (2.71(1.22-4.1 ) vs. 1.7(0.16-5.1); p=0.02; and 677.8(215-1322) vs. 294.6(69.49-799.1), respectively; p=0.012). Analysis of the receiver operating curve found that 328.49 is the ideal cutoff value for SII to predict mortality with a sensitivity of 83% and a specificity of 68%(area under the receiver operating characteristic curve = 0.814 (95% confidence interval: 0.671-0.956), p=0.005 ). Analyzing the influence of risk factors on survival using Cox regression analysis, SII was discovered as a significant predictor of survival in the study(HR =1.001, 95% CI =1-1.20; p=0.049). SII may be used to predict the overall survival of NB patients.